If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
557.00    0.00 (0.00%)
Bid:
556.50
Ask:
557.00
Spread: 0.50 (0.09%)
Market Cap: £2.47b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director/PDMR Shareholding

8 Jul 2015 14:52

Tate & Lyle PLC

Director/PDMR Shareholding

Tate & Lyle PLC (the “Company”) announces that it was informed yesterday that on 7 July 2015, a grant of options and awards over the Company’s ordinary shares of 25 pence each in the capital of the Company (“Shares”) was made to Persons Discharging Managerial Responsibilities (“PDMR”) and to an Executive Director as follows:

1. PDMRs

Name Role Number of Shares subject to option* Number of Shares subject to award*
Rowan Adams PDMR 35,000 -
Joan Braca PDMR - 90,000
Robert Gibber PDMR 110,000 -
Rob Luijten PDMR 80,000 -
Gabrielle Parisse PDMR - 70,000
Pierre Schoumacher PDMR - 70,000

* Options are generally granted to UK residents and awards to non-UK residents.

The above options and awards will only vest to the extent that certain Company-based financial performance criteria are satisfied over a performance period which runs from 1 April 2015 to 31 March 2016. No consideration is payable for the grant or exercise of the options or awards. Options and awards will be subject to a 12-month deferral period and continued employment to 31 March 2017.

2. Nick Hampton

As explained on pages 71 and 72 of the Company’s Annual Report 2015, Nick Hampton, Chief Financial Officer, was granted an award in the form of a nil cost option over 121,781 ordinary shares of 25 pence each in the capital of the Company (the “Award”).

The Award was granted in connection with Mr Hampton’s recruitment as Chief Financial Officer and is intended to honour the agreement (announced on 24 June 2014) to compensate him for incentive awards that he forfeited at his previous employer.

The Award which is within the shareholder approved remuneration policy (for recruitment) has been granted following consultation with major shareholders. As a condition of the grant of the Award, Mr Hampton has surrendered the compensatory Award C that was granted to him on 18 November 2014 with a face value at the time of £1.44m.

The Award will be available for exercise by Mr Hampton after 31 March 2017.

Following the grant of the Award, the incentive arrangements relating to the recruitment of Mr Hampton are as follows:

Award name Date of grant Number of Shares subject to option Vesting Date
Award A 18/11/2014 96,681 01/09/15
Award B 18/11/2014 96,680 01/09/16
Award C – replacement 07/07/2015 121,781 After 31/03/17

All the above transactions took place in London.

This notification is made in accordance with DTR 3.1.4R(1)(a) of the FCA’s Disclosure and Transparency Rules.

Lucie Gilbert

Company Secretary

8 July 2015

Note:

Extract from the announcement issued on 24 June 2014:

To compensate Nick for incentive awards that he will forfeit at PepsiCo Europe, Tate & Lyle will make him a one-off Restricted Stock Award (RSA) of £1,200,000 worth of shares in Tate & Lyle (delivered in two equal tranches on the first and second anniversaries of his employment with Tate & Lyle subject to achievement of performance conditions) (Award A and B). In addition, he will receive a PSP award in 2014 of £1,440,000 worth of shares in Tate & Lyle (Award C). The foregoing RSA and PSP award will be subject to forfeiture/repayment if he ceases to be employed in the first 36 months of employment due to his resignation or dismissal for cause.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150708005829/en/

Copyright Business Wire 2015

Date   Source Headline
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.